Celator Pharmaceuticals Phase 3 Trial of VYXEOS™ (CPX-351) Reaches Required Number of Events for Overall Survival Analysis

Celator Pharmaceuticals, Inc. (NASDAQ:CPXX) announced that the Phase 3 clinical trial of VYXEOS™ Liposome for Injection in patients with untreated high-risk acute myeloid leukemia has reached its pre-specified number of events required for the analysis of overall survival. The company expects to announce overall survival results later this quarter.
According to the press release:

The study enrolled 309 patients between the ages of 60 and 75 who had pathologically confirmed diagnosis of high-risk AML by WHO criteria including: therapy-related AML, AML with a history of myelodysplasia (MDS), AML with a history of chronic myelomonocytic leukemia (CMMoL), and de novo AML with karyotypic abnormalities characteristic of MDS.

Click here to view the full press release.